Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Current hematologic malignancy reports - 1 Dec 2019

Shanmuganathan Naranie, Branford Susan

Abstract excerpt

PURPOSE OF REVIEW: Identification of the BCR-ABL1 fusion oncogene in patients diagnosed with chronic myeloid leukemia (CML) led to the development of targeted therapy responsible for the dramatic survival benefits observed in the past two decades. However, despite these revolutionary findings, there remains marked disparity in patient outcomes. Why do some patients present de novo while others evolve to the more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Susceptibility
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Pluripotent Stem Cells

Share to Precancerous Conditions

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 31696382
DOI: 10.1007/s11899-019-00549-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?PMID 31696382Read ↗

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read ↗

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CMLSemantic proximity Read ↗

Chronic Myeloid Leukemia: Beyond BCR-ABL1Semantic proximity Read ↗

Natural course and biology of CML.Semantic proximity Read ↗

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateSemantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

CML - Not only BCR-ABL1 mattersSemantic proximity Read ↗

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.Semantic proximity Read ↗

Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia.Semantic proximity Read ↗

Resistance to Imatinib: Mechanisms and ManagementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.